Improved lipid lowering activity of bezafibrate following continuous gastrointestinal administration: Pharmacodynamic rationale for sustained release preparation of the drug

Pharmaceutical Research

Volumn 16, Issue 7, 1999, Pages 1093-1097

  Hoffman, Amnon ^a   Lomnicky, Yossef ^a   Luria, Myron H ^b   Gilhar, Dalia ^a   Friedman, Michael ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Bezafibrate; Hyperlipidemia; Pharmacodynamics; Pharmacokinetics; Sustained release

Indexed keywords

BEZAFIBRATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COLON ABSORPTION; DISTRIBUTION VOLUME; DRUG ACCUMULATION; DRUG EFFICACY; GASTROINTESTINAL TRACT; HYPERLIPIDEMIA; INTRADUODENAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MATRIX TABLET; NONHUMAN; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN BINDING; RAT; SUSTAINED RELEASE PREPARATION;

ANIMALS; ANTILIPEMIC AGENTS; BEZAFIBRATE; CHOLESTEROL; CHOLESTEROL, DIETARY; CHOLESTEROL, HDL; DELAYED-ACTION PREPARATIONS; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION ROUTES; DUODENUM; ENZYME INHIBITORS; HYPERLIPIDEMIAS; LIPASE; LIPIDS; LIPOPROTEINS, HDL; MALE; POLYETHYLENE GLYCOLS; RATS; RATS, INBRED LEW; SURFACE-ACTIVE AGENTS;

EID: 0032812725     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1018900219616     Document Type: Article

References (10)

1. K. L. Goa, L. B. Barradell, and G. L. Plosker. Bezafibrate: An update of its pharmacology and use in the management of dyslipidaemia. Drugs 52:725-753 (1996).
2. A. Krishnamurthy and G. S. Thapar. Effect of bezafibrate and nicotinic acid on triton induced hyperlipidemias in CFY rats. Indian J. Med. Res. 94(B):395-398 (1991).
3. D. Castoldi, V. Monzani, and O. Tofanetti. Determination of bezafibrate in human plasma and urine by high-performance liquid chromatography. J. Chromatogr. 344:259-265 (1985).
4. D. S. Young, L. C. Pestaner, and V. Gibberman. Effects of drugs on clinical chemistry tests. Clin. Chem. 21:1D-432D (1975).
5. Y. Lomnicky, M. Friedman, M. H. Luria, I. Raz, and A. Huffman. The effect of mode of administration on the hypolipidemic activity of niacin: Continuous gastrointestinal administration of low-dose niacin improves lipid-lowering efficacy in experimentally-induced hyperlipidemic rats. J. Pharm. Pharmacol. 50:1233-1239 (1998).
6. P. E. Schurr, J. R. Schultz, and T. M. Parkinson. Triton-induced hyperlipidemia in rats animal model for screening hypolipidemic drugs. Lipids 7:68-74 (1972).
7. T. E. Strandberg and R. S. Tilvis. Physiological and pharmacological regulation of small intestinal cholesterol. Gen. Pharmacol. 19:321-329 (1988).
8. A. Mallordy, H. Poirier, P. Besnard. I. Niot, and H. Carlier. Evidence for transcriptional induction of the liver fatty-acid-binding-protein gene by bezafibrate in the small intestine. Eur. J. Biochem. 227:801-807 (1995).
9. D. R. Jones, S. D. Hall, E. K. Jackson, R. A. Branch, and G. R. Wilkinson. Brain uptake of benzodiazepines: effects of lipophilicity and plasma protein binding. J. Pharmacol. Exp. Ther. 245:816-822 (1988).
10. T. H. Lin and J. H. Lin. Effects of protein binding and experimental disease slates on brain uptake of benzodiazepines in rats. J. Pharmacol. Exp. Ther. 253:45-50 (1990).